Zohydro's second act

Share this article:

Part two of the Zohdyro painkiller portfolio is coming: drugmaker Zogenix announced Wednesday that it is working on a harder-to-abuse extended release version of its prescription opioid medication.

Lawmakers, addiction advocates and attorneys general have lobbied the FDA to overturn its approval of the drug's first iteration over concerns about how easily it could be abused. Painkiller use, abuse and related deaths have become a major concern. The Centers for Disease Control and Prevention reported Tuesday that US physicians wrote enough painkiller prescriptions in 2012 to give every adult a full bottle.

The CDC says that, on average, 46 people die each day from prescription painkillers. Although the government agency notes that New York, Tennessee and Florida have been successful in cracking down on patients who doctor-shop for prescriptions or limiting where the drugs can be distributed, a true solution will require multiple types of interventions.

The CDC's report indicates as much: the government agency noted that Florida's heroin-, hydromorphone- and morphine-related deaths rose between 2010 and 2012, the same period when the number of prescriptions for opioid painkillers fell in the state. The CDC wrote this inverse relationship “might be a sign of a switch to use of alternative opioids.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.